Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 29;11(1):39.
doi: 10.3390/antibiotics11010039.

PEG-Functionalized Magnetite Nanoparticles for Modulation of Microbial Biofilms on Voice Prosthesis

Affiliations

PEG-Functionalized Magnetite Nanoparticles for Modulation of Microbial Biofilms on Voice Prosthesis

Mara Caciandone et al. Antibiotics (Basel). .

Abstract

This study reports the fabrication of nanostructured coatings based on magnetite, polyethyleneglycol, and biologically active molecule (polymyxin B-PM) for producing biofilm-resistant surfaces (voice prosthesis). Magnetite nanoparticles (MNPs) have been synthesized and functionalized using a co-precipitation method and were further deposited into thin coatings using the matrix-assisted pulsed laser evaporation (MAPLE) technique. The obtained nanoparticles and coatings were characterized by X-ray diffraction (XRD), thermogravimetric analysis with differential scanning calorimetry (TGA-DSC), scanning electron microscopy (SEM), transmission electron microscopy with selected area electron diffraction (TEM-SAED), Fourier-transform infrared spectroscopy (FT-IR), and infrared microscopy (IRM). Their antibiofilm activity was tested against relevant Staphylococcus aureus and Pseudomonas aeruginosa bacterial strains. The Fe3O4@PEG/PM surface of modified voice prosthesis sections reduced the number of CFU/mL up to four orders of magnitude in the case of S. aureus biofilm. A more significant inhibitory effect is noticed in the case of P. aeruginosa up to five folds. These results highlight the importance of new Fe3O4@PEG/PM in the biomedical field.

Keywords: PEG; antibiofilm activity; antimicrobial coatings; antimicrobial resistance; magnetite nanoparticles; matrix assisted pulsed laser evaporation; polymyxin B.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
X-ray diffractogram of Fe3O4, Fe3O4@PEG, and Fe3O4@PEG/PM.
Figure 2
Figure 2
SAED pattern (a), HR-TEM image (b), and TEM images (c,d) of Fe3O4@PEG/PM; (e) size distribution.
Figure 3
Figure 3
FT-IR spectrum of Fe3O4@PEG/PM nanoparticles.
Figure 4
Figure 4
Thermogravimetric analysis of Fe3O4 nanoparticles.
Figure 5
Figure 5
Thermogravimetric analysis of Fe3O4@PEG nanoparticles.
Figure 6
Figure 6
IR maps of Fe3O4@PEG (1,2) and Fe3O4@PEG/PM (3,4,5); dropcast (a), F = 300 mJ/cm2 (b), F = 400 mJ/cm2 (c), F = 500 mJ/cm2 (d), based on the distribution of C-H (1), C-O (2), C-H (3), C-O (4) and (C=O (5), assigned to PEG (1,2,3,4) and PM (5).
Figure 7
Figure 7
IR spectra of Fe3O4@PEG (1) and Fe3O4@PEG/PM (2): dropcast (a), F = 300 mJ/cm2 (b), F = 400 mJ/cm2 (c), F = 500 mJ/cm2 (d).
Figure 8
Figure 8
SEM images of Fe3O4@PEG (1) and Fe3O4@PEG/PM (2): (a) cross-section; (b) coatings surface.
Figure 9
Figure 9
Evaluation of biofilm development after 24 and 48 h of incubation in the presence and absence of PEG-based thin film for S. aureus strain.
Figure 10
Figure 10
Evaluation of biofilm development after 24 and 48 h of incubation in the presence and absence of PEG-based thin film for P. aeruginosa strain.
Figure 11
Figure 11
Morphology of MC3T3-E1 osteoblasts cultivated in the absence (control) and presence of Fe3O4@PEG and Fe3O4@PEG/PM samples.
Figure 12
Figure 12
Cell viability and nitric oxide concentration after 24 h of incubation of MC3T3-E1 osteoblasts with Fe3O4@PEG and Fe3O4@PEG/PM samples. The measurements were performed in triplicate (n = 3) and the results were presented as average ± standard deviation relative to the control.

References

    1. Pfizer. The Value of Antibiotics in Treating Infectious Diseases. [(accessed on 20 September 2021)]. Available online: https://www.pfizer.com/news/featured_stories/featured_stories_detail/the....
    1. Aminov R.I. A brief history of the antibiotic era: Lessons learned and challenges for the future. Front. Microbiol. 2010;1:134. doi: 10.3389/fmicb.2010.00134. - DOI - PMC - PubMed
    1. Hutchings M.I., Truman A.W., Wilkinson B. Antibiotics: Past, present and future. Curr. Opin. Microbiol. 2019;51:72–80. doi: 10.1016/j.mib.2019.10.008. - DOI - PubMed
    1. Podgoreanu P., Negrea S.M., Buia R., Delcaru C., Trusca S.B., Lazar V., Chifiriuc M.C. Alternative strategies for fighting multidrug resistant bacterial infections. BioInterface Res. Appl. Chem. 2019;9:3834–3841. doi: 10.33263/briac91.834841. - DOI
    1. Spirescu V.A., Chircov C., Grumezescu A.M., Andronescu E. Polymeric Nanoparticles for Antimicrobial Therapies: An up-to-date Overview. Polymers. 2021;13:724. doi: 10.3390/polym13050724. - DOI - PMC - PubMed

LinkOut - more resources